Volume 89 Issue 9 | pp. 36-38
Issue Date: February 28, 2011

Pharma’s Next Transformation

Companies continued to overhaul R&D amid tepid fourth-quarter results
Department: Business
Keywords: Pfizer, Merck, GSK, Sanofi, earnings, pipeline, pharmaceuticals

Patent expiries, stalled new-drug pipelines, pricing pressures, and health care reform costs created pain for drug companies in both the fourth quarter of 2010 and the full year. Due in part to the arrival of generic competition to key products in the year’s second half, fourth-quarter profits dropped at more than half of the 11 drug firms C&EN tracks.

Despite the already deep cuts made across the pharmaceutical industry from 2008 to 2010, several companies . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society